Actelion seeks transparency and dialogue with all its stakeholders to improve its understanding of their needs. These stakeholders include patients, healthcare providers, shareholders, employees, governmental authorities, the environment and the communities where Actelion is present. We consult and engage with all our stakeholders on a regular basis and incorporate their feedback into the company’s strategy and risk management. We also participate in annual surveys, responding with detailed information requested by stakeholders such as the Carbon Disclosure Project (CDP) and the Dow Jones Sustainability Indices (DJSI) in collaboration with RobecoSAM.
We engage with patient organizations and healthcare providers to better understand patients and their caregiver’s needs. This includes working with, and supporting, patient groups, as well as discussing with healthcare professionals the broader range of disease challenges they and their patients face. Our ongoing aim is to ensure that all of our relationships with patient groups and other healthcare organizations continue to be based on transparency, trust and a shared objective to improve the lives of patients.
Our day-to-day business activities include regular contact with physicians and other healthcare professionals. Our communications focuses on providing information about our medicines, the diseases they treat and the benefits and risks associated with their use.
Actelion regularly offers the availability of Investor Relations personnel and senior management to the company’s capital market stakeholders. This includes presenting the company’s progress and opportunities for future growth at healthcare conferences, and visiting its clients to offer a better understanding of the company, its performance and its growth potential.
Where possible Actelion also welcomes institutional investors and sell-side analysts to its headquarters to experience the company's culture and view the established drug discovery capabilities.
Actelion also holds an Annual General Meeting of shareholders as an opportunity for the Board of Directors to report to the company’s shareholders on the progress made in the previous 12 months.
Actelion can only achieve its ambitious goals and deliver on our mission to treat more patients with ground-breaking therapies if we have an engaged workforce, with a clear sense of purpose and confidence in their abilities. To achieve this we recognize the need to provide effective leadership, clear targets, open lines of communication, learning and development opportunities and a safe workplace.
In addition to global employee briefings and many local team, department and location meetings, we use a wide range of electronic media to communicate regularly with our employees around the world.
Feedback opportunities are integrated into our internal communication programs and, in addition, our Code of Conduct outlines the procedures for employees to raise any potential concerns that he or she may have. At headquarters, employees have an elected Employee Representative Council (ERC) who management meets with regularly.
As we seek to have a positive impact on the lives of our patients and employees and in the communities where we operate, we also strive to minimize our impact on the environment.
Actelion has responded to the call for greater corporate climate accountability by providing full transparency on its energy use. With a disclosure score in the top 10% of reporting companies, Actelion is now part of the CDP Climate Disclosure Leadership Index.
Actelion’s community support is consistent with our goals of improving health and quality of life, as well as promoting science among young people.
To maximize their value and impact, projects are usually identified and managed locally. We encourage our people to involve themselves in projects in their communities, both because of what they can contribute and because community service is a personally enriching experience.
In addition, we back our employees activities by matching their donations for humanitarian causes. Following the devastating typhoon which struck the Philippines in November 2013, our employees raised over CHF 40,000 for the relief efforts, and this contribution was doubled by Actelion.
At headquarters in Switzerland, employees have the opportunity, through the Swiss Red Cross, to donate blood twice per year for the local blood bank.